Tonix Pharmaceuticals Holdin (TNXP) 13F Holders & Ownership Data (104 Funds, Q2 2026)

TNXP ranks #4503 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

TNXP is a disclosed holding of Steve Cohen (Point72 Asset Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

104 institutions disclose a position in TNXP, but none treat it as a major bet — even Ishara Investments LP, its most concentrated holder, allocates just 3.2% of its own portfolio to it.

Israel Englander has added to its TNXP position for two straight quarters, increasing it by $12.0M to reach $12.3M today.

Morgan Stanley has trimmed its TNXP position for two straight quarters, cutting it by $462.2K while still holding $194.5K.

TNXP is down 4.3% today, but institutions show net buying of $60.9M this quarter — a divergence between today's price move and the underlying institutional flow.

TNXP reported a net loss of $159.7M over the trailing twelve months.

• Not yet profitable — net loss of $159.7M over the trailing twelve months
• Revenue grew 196.0% year over year
• Net income declined year over year, from -$81.4M to -$159.7M
• Operating cash flow was negative, using $99.8M in cash
• Current ratio of 7.42x — enough short-term assets to cover short-term liabilities
• Liabilities run 2463.15x equity — a highly leveraged balance sheet worth noting